49results about How to "Improving immunogenicity" patented technology

The invention belongs to the field of veterinary biological products, and particularly relates to a chicken infectious laryngotracheitis recombinant subunit vaccine as well as a preparation method and application thereof. A core antigen of the vaccine is a recombinant gB trimer glycoprotein (gB-Trimer) modified by genetic engineering, and the protein successfully locks a prefusion conformation with the strongest immunogenicity of the gB protein through strategies of truncation, trimerization motif splicing, dual-stability mutation and the like. The vaccine prepared by the invention can stimulate rapid and lasting neutralizing antibody response, provide 100% clinical protection and effectively block replication and detoxification of the ILTV, has extremely high biological safety compared with a traditional live vaccine, completely eliminates risks of poison dispersion and enhancement, and provides a safe and efficient novel solution for prevention and control of the ILTV.

This invention relates to the field of biomedical technology, specifically to HCBP6 monoclonal antibodies and their applications. This invention utilizes bioinformatics databases and online tools to analyze the structure of the HCBP6 protein, screening for highly immunogenic HCBP6 antigen peptides. Antibody 1 and Antibody 2 are obtained through immunization. The combination of Antibody 1 and Antibody 2 is used for the detection of HCBP6, exhibiting high sensitivity and good detection results. It has significant development and application value and long-term implications for the auxiliary diagnosis of fatty liver.

The application discloses a kind of avian influenza and avian infectious bronchitis two-union recombinant subunit vaccine and its preparation method and application.The recombinant protein is by replacing the head domain of AIV HA protein with the RBD domain of IBV S protein, while adding GCN4, Trimer-tag trimer tag in sequence, the recombinant protein obtained, the recombinant protein is expressed in vitro using insect cells and prepared into subunit vaccine.The vaccine prepared by the application can produce high-level neutralizing antibodies against homologous and heterologous H9N2 subtype avian influenza virus after immunizing chicken population, while significantly reducing the virus discharge level and the histopathological changes caused, and can also induce high-level specific antibodies and neutralizing antibodies against QX subtype avian infectious bronchitis virus, effectively inhibit discharge, viral load, and reduce tissue lesions.The application does not depend on chicken embryo, and has low production cost and short cycle, and can simultaneously prevent avian influenza and avian infectious bronchitis.

The application discloses Metrnl-a gene and application thereof in preparation of a DNA vaccine molecular adjuvant for grass carp hemorrhagic disease, and relates to the technical field of aquatic immunology and biological agents. The molecular adjuvant is that a grass carp Metrnl-a gene is constructed into a eukaryotic expression vector pcDNA3.1 to obtain a recombinant eukaryotic expression vector pcDNA3.1-Metrnl-a of the grass carp Metrnl-a. The pcDNA3.1-Metrnl-a plasmid and the pcDNA3.1-VP35 DNA vaccine can be stably expressed in the grass carp through muscle injection, significantly enhance the expression of immune-related genes and the antibody titer, significantly reduce the VP56 virus titer in the grass carp after challenge, and increase the survival rate of the grass carp after infection with grass carp reovirus by about 13.3%. The molecular adjuvant can effectively enhance the immune effect of the DNA vaccine of the grass carp and has a good application prospect.

The invention belongs to the technical field of biological medicine, and particularly relates to a PDHC mutant, an immunogenic fragment and application, the PDHC mutant has amino acid mutation at at least one of the 214th site, the 274th site or the 294th site of the amino acid sequence shown in SEQ ID NO: 1, and the PDHC mutant is used for preventing or treating staphylococcus aureus (SA) infection and is an mRNA vaccine for preventing or treating staphylococcus aureus (SA) infection. The stability and immunogenicity of the staphylococcus aureus PDHC antigen are greatly improved, efficient targeted delivery of the antigen is achieved, and the immune effect of the vaccine is remarkably improved.

The present application relates to a kind of mycophenolic acid detection reagent and its preparation and detection method, specifically a kind of mycophenolic acid chemiluminescence immunoassay reagent and its preparation and detection method, comprising: anti mycophenolic acid specific antibody, for detecting the indicating reagent of anti mycophenolic acid specific antibody-mycophenolic acid combination;The above anti mycophenolic acid specific antibody is obtained by mycophenolic acid immunogen immunization animal.The present application has the advantages that: the mycophenolic acid immunogen of the present application is specific, and immunogenicity is high, and the prepared anti mycophenolic acid specific antibody is specific, and titer is high;Chemiluminescence immunoassay reagent containing the above anti mycophenolic acid specific antibody can determine the mycophenolic acid content in sample conveniently, quickly and accurately, and multiple samples can be simultaneously determined on full-automatic chemiluminescence immunoassay analyzer, realize the high-throughput rapid determination of mycophenolic acid, and the accuracy is high, and the specificity is strong, and accuracy and detection efficiency have been greatly improved.

This invention discloses a hapten, an artificial antigen, and their applications for detecting paclobutrazol. The paclobutrazol hapten prepared by this invention retains the characteristic structure of paclobutrazol to the greatest extent possible. The paclobutrazol antibody prepared using the paclobutrazol hapten of this invention exhibits high potency and specificity, with a half-maximum inhibitory concentration (WMC) of 0.31 ng / mL and a linear range of 0.03–19.63 ng / mL. Furthermore, it shows no cross-reactivity with other structural and functional analogs such as uniconazole and hexaconazole. This invention simplifies the synthesis steps of the paclobutrazol hapten, and the method for preparing the paclobutrazol artificial antigen and its antibody is simple and low-cost. It also establishes a more efficient immunoassay method, capable of meeting the requirements for large-scale on-site sample testing and has broad application prospects.

The invention relates to the technical field of veterinary drugs, and particularly provides a polynucleotide molecule composition for preventing cat infectious peritonitis, a chimeric polynucleotide molecule and an mRNA vaccine. In order to overcome the ADE effect caused by S protein full-length antigen in the prior art, FIPV N protein without ADE risk is adopted and is combined with screened S protein specific T cell and B cell epitopes. Core schemes include two classes: one is a separate polynucleotide composition comprising epitope peptides encoding N and S proteins; and 2, a single chimeric polynucleotide encoding N protein and S protein epitope peptides. The polynucleotides are optimized by codons and encapsulated in lipid nanoparticles (LNP) to prepare vaccines. Experiments prove that the vaccine can synergistically stimulate powerful immune response, the survival rate of immune cats is remarkably increased to 80%-100% from standard 40% on the premise that ADE is not caused, and FIP is effectively prevented.

The present application relates to the animal medical technology field, especially to the Streptococcus suis strain and the vaccine thereof for prevention and treatment, and provides Streptococcus suis type 2, type 3 and type 9 strains screened and obtained, and a trivalent inactivated vaccine prepared by mixing the three strains, which can safely and effectively prevent and protect against the attack of the three pathogenic bacteria of Streptococcus suis.

The application provides a hybridoma cell strain secreting a monoclonal antibody against a alginate mannuronic acid tetrasaccharide epitope, a monoclonal antibody and application. In order to enhance the immunogenicity of the mannuronic acid tetrasaccharide, a glycoconjugate KLH-1 is used as an immunogen to inject and immunize a mouse, so that the mouse is stimulated to produce a specific immune response against the mannuronic acid tetrasaccharide epitope, then spleen cells of the immunized mouse are fused with myeloma cells, and after screening, an initial hybridoma cell strain is obtained; then after subcloning and specific screening, a hybridoma cell strain capable of stably secreting a monoclonal antibody of the target mannuronic acid tetrasaccharide epitope in alginate is obtained, and a monoclonal ascites antibody is further obtained. The monoclonal ascites antibody shows specific recognition and combination ability for pseudomonas aeruginosa, and the combination activity is related to the expression level of alginate on the surface of the bacteria. Therefore, the monoclonal ascites antibody can be used as a precise detection and diagnosis tool for pseudomonas aeruginosa, and can also be applied to the antibacterial treatment of pseudomonas aeruginosa infection.

This invention discloses chloramphenicol hapten, antigen, antibody, colloidal gold detection device, and their preparation methods and applications. The chloramphenicol hapten prepared by this invention using a total synthesis method retains all potential recognition sites of chloramphenicol to the maximum extent, and in particular, for the first time retains the most critical dichloro structure of chloramphenicol. After introducing a spacer arm, its electron cloud distribution is almost identical to the overall electron cloud distribution of chloramphenicol, improving the immunogenicity of the chloramphenicol antigen. The chloramphenicol antigen and monoclonal antibody prepared by this invention have high specificity for ELISA detection, with an IC50 value of [missing information]. 50 The value was 8.21 pg / mL, the linear detection range was 1.71–39.45 pg / mL, the cross-reactivity to common structural analogs was less than 0.01%, and the sensitivity to chloramphenicol in the sample was 0.1 µg / kg.

The application discloses a Gitta virus genetically engineered subunit vaccine and a preparation method and application thereof, and belongs to the technical field of vaccine preparation. The Gitta virus P6E recombinant protein is obtained by using a eukaryotic expression system, and is further loaded on the surface of a nanoparticle skeleton to form a recombinant nanoparticle. The obtained recombinant protein and the recombinant nanoparticle are respectively compounded with an adjuvant to prepare the genetically engineered subunit vaccine. After twice immunization, the vaccines of the two components can significantly induce the host to produce strong humoral immune and cellular immune responses, thereby providing effective protection against GETV infection. The technical scheme of the application provides an important technical basis and application reference for research and optimization of the Gitta virus vaccine.

This application relates to the field of antibody technology, specifically providing a truncated fragment of the African swine fever virus pB602L protein, an antibody thereof, or an antigen-binding fragment thereof, and their applications. The truncated fragment, encoded by SEQ ID NO.1, eliminates mismatched disulfide bonds and repetitive sequences by deleting the first 200 amino acids from the N-terminus, thereby improving protein solubility and immunogenicity. The antibody thereof or its antigen-binding fragment contains the heavy chain variable region shown in SEQ ID NO.2 and the light chain variable region shown in SEQ ID NO.4, exhibiting a blocking rate of greater than 90% against the pB602L protein. This truncated fragment and antibody demonstrate high specificity and sensitivity, and can be used for the detection, diagnosis, and evaluation of vaccine immunization efficacy for African swine fever virus, providing an important tool for the prevention and control of African swine fever.

The invention relates to a respiratory syncytial virus vaccine composition and application thereof. The recombinant respiratory syncytial virus vaccine comprises RSVpreF protein and a pharmaceutically acceptable composite adjuvant carrier, and the composite adjuvant carrier is formed by combining an aluminum adjuvant with a CpG adjuvant. Experimental results prove that the vaccine composition provided by the invention has good immunogenicity and a better immune effect.

This invention discloses a mutant attenuated strain of avian reovirus genotype II, wherein the σC protein amino acid sequence of the mutant strain includes mutations at positions 40, 45, 111, 180, 244, 273, and 300. Due to this mutation, compared to the parent wild-type strain, the pathogenicity to SPF chickens is significantly reduced, it does not cause persistent footpad swelling, and the viral load and shedding levels in tissues are extremely low, without affecting weight gain. Immunopotency evaluation shows that this mutant attenuated strain can induce high levels of specific antibodies, effectively controlling clinical symptoms, viral load in tissues, and shedding. This invention provides a safe and highly effective attenuated vaccine candidate strain for the prevention and control of avian reovirus genotype II, filling a corresponding technological gap.

The application provides a fusion polypeptide and application thereof, takes MG7-Ag single epitope as a target antigen (MG1) of a digestive tract tumor, and is composed of a T helper epitope peptide and three MG1 in series which are connected by a covalent amide bond at an N terminal, wherein, an adapter lysine residue is removed at a splicing position of adjacent MG1 segments of the MG3. The application covalently couples the T helper epitope peptide at the N terminal of the MG3, and relies on a Th epitope to mediate an MHC II class pathway to present, strongly activates a helper T cell, greatly improves an anti-MG1 specific IgG production capacity, and solves a natural immunogenicity deficiency defect of the MG1 from a molecular structure level.

This invention discloses a type B influenza virus T4 peptide that can induce cellular immune responses and its applications, belonging to the fields of immunotherapy and immunoassay technology. The immunogenicity of this long peptide (SEQ ID NO.1, named T4) was verified in 21 volunteers using ELISpot assay. Results showed that T4 was positive in 5 individuals, with a positive rate of 23.81%. ELISpot assay of human PBMCs (IFN-γ secretory cells) showed that T4 induced an immune response of up to 3060 SFCs / 10 in the population. 6 PBMC. Therefore, this peptide has good immunogenicity and universality in the population, and can be used as a specific detection peptide for monitoring cellular immune levels. At the same time, this peptide can effectively activate the T cell immune response in the population, and has the potential to be used as a candidate vaccine epitope peptide for the design of novel vaccines.

This invention provides a method for preparing influenza virus hemagglutinin protein HA and its application, belonging to the field of biopharmaceutical technology. The method utilizes engineered cell chassis cells with glycosylation modification capabilities. After fermentation expression, the expressed protein from the engineered cells is extracted in a single step to obtain a crude extract containing the target antigen. The crude extract obtained from the engineered cells constructed in this invention, after induction, has the potential to serve as a candidate for a dual-route vaccine (intramuscular injection and mucosal immunization), providing a new technical approach for the multi-route immunization development of influenza vaccines.

This invention discloses a genetically modified attenuated strain of Mycobacterium bovis, its construction method, and its applications. Utilizing the principle of homologous recombination, the RD1 region of the genome is knocked out and membrane protein genes are inserted to construct a candidate strain for an attenuated live vaccine. This strain can be used as an immunotherapeutic agent for bladder cancer or as an attenuated live vaccine for tuberculosis. This invention is based on the virulent strain of Mycobacterium bovis AF2122 / 97. By genetically modifying it to knock out its RD1 region to reduce its virulence while retaining cell wall antigens (such as MPB70 / 83), and simultaneously inserting antigen fragments related to the deleted region, it enhances its immunogenicity.

The application provides a pertussis antigen recombinant expression vector and engineering bacteria and application thereof. The pertussis antigen recombinant expression vector comprises a resistance screening gene, an upstream recombinant nucleic acid fragment of a pertussis exotoxin gene and a downstream recombinant nucleic acid fragment, wherein the upstream and downstream recombinant nucleic acid fragments can respectively perform homologous recombination with the upstream and downstream of the pertussis exotoxin gene. The application takes the pertussis bacillus as a host, constructs an engineering bacteria ΔPT strain for producing FHA and PRN by knocking out the PT gene, simplifies the production process of the FHA and PRN antigens, maintains the high purity and immunogenicity of the FHA and PRN antigens, eliminates the interference of the PT protein in the production of the FHA and PRN antigens, avoids the PT protein detoxification process, and eliminates the risk of possible PT protein toxicity reversal.

The invention relates to the field of biotechnology and biological products, in particular to a bordetella bronchiseptica attenuated strain and application thereof. The bordetella bronchiseptica low virulent strain which is remarkably weakened in virulence and keeps high immunogenicity is obtained in a continuous passage and genome sequencing mode, the remarkable virulence weakening characteristic is shown, dog diseases cannot be caused, and the high immunogenicity is achieved. The low virulent strain is used for preparing a bordetella bronchiseptica vaccine, can efficiently stimulate the specific immune response of dog and cat organisms, reduces the repeated inoculation frequency, and avoids the environmental transmission risk of toxic strains from the source. The screened Bordetella bronchiseptica attenuated strain does not contain any exogenous nucleic acid, the genetic background of the strain is clear and traceable, the biological safety requirement of veterinary vaccines is completely met, and a safe and reliable brand-new scheme is provided for dog and cat health protection.

The application discloses a Candida albicans bivalent subunit vaccine fusion protein and a preparation method and application thereof, and relates to the technical field of biological medicines. The fusion protein is formed by connecting a Candida albicans Sap2 truncated fragment (SEQ ID NO: 1) and a Cht3 truncated fragment (SEQ ID NO: 2) through a flexible linker (SEQ ID NO: 3). The application further provides a nucleotide sequence encoding the fusion protein, a vaccine containing the fusion protein and a pharmaceutically acceptable adjuvant, and application of the fusion protein in preparation of a medicine or vaccine for preventing Candida albicans infection. The fusion protein is recombinantly expressed, enzymatically cut on a GST affinity chromatographic column and refined through ion exchange chromatography, and the purity can reach more than 95%. The fusion protein is significantly superior to a Sap2 and Cht3 physical mixing group, has an immune synergistic enhancement effect, and can be used for preventing Candida albicans infection.

This invention belongs to the field of veterinary biological products technology, specifically relating to a chicken-derived serum type 7 of *Rimerella anatipestifer* and its application. *Rimerella anatipestifer* (… Riemerella anatipestifer HD24 has been deposited at the China General Microbiological Culture Collection Center (CGMCC) on March 18, 2026, with accession number CGMCC No. 37707. The inactivated vaccine using the HD24 strain exhibits an 80% immunoprotective rate, demonstrating its good immunogenicity and safety. This provides an ideal candidate strain for the development of inactivated chicken rabies (RA) vaccines, addressing the current shortage and lack of specificity of chicken-derived RA vaccines, and offering a new technical solution for the proactive prevention and control of RA infection in chicken flocks.

The application discloses a fusion protein HP16118P and application thereof in differential diagnosis of latent infection of mycobacterium tuberculosis. Specifically disclosed is a fusion protein comprising HTL, CTL and B cell epitope in series, HBD-3, PADRE and PSM alpha 4. The application screens 35 epitopes for mycobacterium tuberculosis, which have good immunogenicity and antigenicity and no toxicity, no sensitization and other characteristics. Further, the auxiliary peptides HBD-3 and PADRE are added to improve the immunogenicity of the fusion protein, and the PSM alpha 4 is added to endow the fusion protein with a targeted delivery function. In vitro experiments prove that the HP16118P can stimulate human peripheral blood mononuclear cells to produce an immune response, and is a dominant protective antigen. The HP16118P has the advantages of simple preparation method, good specificity, high sensitivity, low cost and the like as a diagnostic molecule. The application has great value for differential diagnosis of active tuberculosis and latent tuberculosis infection.

This invention belongs to the field of genetic engineering technology, specifically relating to a double-gene-deleted serotype 5 Haemophilus parasuis attenuated vaccine strain, its construction method, and its application. This invention mainly utilizes modern genetic engineering principles and molecular biology techniques to delete the cpxA and cpxR genes, potential virulence factors of HPS, constructing the HN1570 double-gene-deleted strain HPS5△cpxAR. This double-gene-deleted strain was deposited at the China General Microbiological Culture Collection Center (CGMCC) on June 16, 2023, with accession number CGMCC NO: 45596. Compared with the parent strain, this double-gene-deleted strain exhibits significantly reduced virulence while maintaining the same immunogenicity. The attenuated live vaccine prepared from this strain as an antigen provides 100% protection against serotype 5 infection and good cross-protection against other serotypes and untyped Haemophilus parasuis infections. Furthermore, the vaccine preparation process eliminates the need for inactivation and inactivation testing, simplifying the preparation method and increasing production efficiency. This lays the foundation for further development of novel, highly effective genetically engineered live vaccines that provide high cross-protection efficacy.

The invention discloses a levofloxacin hapten, antigen and antibody as well as a preparation method and application thereof, and belongs to the technical field of small molecule immunodetection.A flexible spacer-(CH2) n-NH2 containing a terminal amino group is introduced to a nitrogen atom (namely a methyl connection site of methyl piperazine) at the tail end of a piperazine ring of a levofloxacin molecule, n is an integer of 2-8, and the flexible spacer-(CH2) n-NH2 is introduced into the nitrogen atom at the tail end of the piperazine ring of the levofloxacin molecule; therefore, a complete antigen with high immunogenicity and high specificity is constructed on the premise that a complete pharmacological structure of a quinolone mother nucleus is reserved, and a high-affinity antibody aiming at levofloxacin is obtained through induction.

The application belongs to the technical field of synthetic biology, and particularly relates to a recombinant I&III fusion type collagen with high stability and low immunogenicity, and a preparation method and application thereof. The amino acid sequence of the recombinant I&III fusion type collagen and the nucleotide sequence of the coding gene thereof are disclosed. The recombinant I&III fusion type collagen with high stability and low immunogenicity is prepared by a fermentation method of an engineering bacterium. The results of examples show that the recombinant I&III fusion type collagen colI&III-1 provided by the application has good thermal stability, long-term stability and anti-degradation capacity. The animal experiment proves that the recombinant I&III fusion type collagen colI&III-1 has low immunogenicity, and does not cause immune balance disorder of animals. In addition, the recombinant I&III fusion type collagen has the characteristics of high biocompatibility and good safety, and has no influence on the overall health condition of animals.

The invention relates to the field of biological pharmacy, in particular to fusion protein, a nano vaccine and application thereof. The fusion protein provided by the invention comprises a fusion protein 1 and / or a fusion protein 2; the fusion protein 1 is prepared from a SpyTag protein and an Rv1498A protein; and the fusion protein 2 comprises a SpyCatcher protein and a gp350 protein. A flavin binding protein Rv1498A in a mycobacterium tuberculosis dodecin-like family is used as a carrier protein, a distal membrane end and a proximal membrane end of an EB virus gp350 extracellular domain are respectively displayed on the surface of the Rv1498A by utilizing a SpyTag-SpyCatcher technology, two immunogenic compounds are obtained, high expression quantity is realized while correct modification and folding of an antigen are ensured, and the EB virus gp350 extracellular domain immunogenic protein Rv1498A can be used for preparing the EB virus gp350 extracellular domain immunogenic protein Rv1498A and the EB virus gp350 extracellular domain Rv1498A immunogenic protein Rv1498A and the EB virus gp350 extracellular domain Rv1498A. And the nano-particle vaccine prepared by the aid of an adjuvant is proved to have better immunogenicity in a mouse body.

The invention belongs to the technical field of biology, and discloses a method for determining a multivalent antigen sequence of an anti-periodontitis red complex, which comprises the following steps: firstly, screening out key virulence factor antigens (FimA-II, RgpA, Msp and BspA) from three core pathogenic bacteria of the red complex: porphyromonas gingivalis, treponema denticola and fusisterone; then, independently cloning each antigen gene to a pUC57 cloning vector, constructing a single antigen recombinant plasmid, and avoiding intergene interference by designing a specific enzyme cutting site; and finally, through plasmid transformation, positive clone screening and double enzyme digestion verification, the plasmid quality is ensured. The obtained single antigen plasmid can be flexibly combined and used, is beneficial to subsequent multivalent vaccine development, and has the advantages of wide antigen coverage, high expression reliability, flexible construction strategy, easiness in industrialization and the like.